A method for identifying constitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
CA 2443795 A1 · Owner: Engelberg, David · Inventors: Levitzki, Alexander; Engelberg, David; Bell, Michal
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method of screening for constitutively active mutants of a desired eukaryotic MAPK pathway member of a MAPK pathway member, comprising the steps of (a) providing a mutant yeast strain devoid of an upstream kinase; (b) providing a DNA library of different mutants of a mutagenized gene coding for the desired MAPK pathway member; (c) introducing said library into said yeast strain under conditions suitable for activation of the yeast MAPK pathway; (d) detecting an end-point indication for activation of the yeast pathway; and (e) optionally isolating said constitutively activated mutant from selected rescued clones. The invention further relates to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 4, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 4, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 4, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.